Progressive Supranuclear Palsy

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Progressive Supranuclear Palsy is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • PSP
  • nuchal dystonia dementia syndrome
  • Steele-Richardson-Olszewski syndrome

Disorder Subdivisions

  • None

General Discussion


Progressive supranuclear palsy (PSP) is an uncommon degenerative neurological disorder that causes progressive impairment of balance and walking; impaired eye movement, especially in the downward direction; abnormal muscle tone (rigidity); speech difficulties (dysarthria); and problems related to swallowing and eating (dysphagia). Affected individuals frequently experience personality changes and cognitive impairment. Symptoms typically begin after age 60 but can begin earlier. The exact cause of PSP is unknown. PSP is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders.


Drs. John C. Steele, J.C. Richardson and J. Olszewski identified progressive supranuclear palsy as a distinct neurological disorder in 1963.


The signs and symptoms of PSP vary from case to case, but patients generally fall into one of four clinical syndromes (phenotypes): Richardson syndrome, atypical parkinsonism, corticobasal syndrome, and pure akinesia and gait freezing. Less commonly, patients present with cognitive loss and no motor signs.

The most common presentation is the Richardson syndrome, consisting of gait and balance impairment, a wide-eyed staring facial expression, abnormal speech, memory and cognitive impairment and a slowing or loss of voluntary eye movement, particularly in the downward direction (supranuclear ophthalmoplegia). Cognitive symptoms include forgetfulness and personality changes, such as loss of interest in formerly pleasurable activities (apathy), impaired attention and concentration, depression, and increased irritability.

Fewer than half of all PSP patients are initially diagnosed correctly because many patients do not present with the classic Richardson syndrome. Many of these patients are initially slow and have muscle rigidity and occasionally tremor, resembling Parkinson disease, and they may initially respond somewhat to levodopa. Other patients present with bizarre stiffening (rigidity and dystonia) and loss of voluntary function in one upper limb, as is seen in corticobasal degeneration. Rarely, patients exhibit the syndrome of primary akinesia and gait freezing. These patients exhibit hesitant initiation of gait and a tendency to freeze or stop when turning and when crossing thresholds (doorways). Their eye movements and cognition are normal. Small handwriting and low-volume rapid, mumbling speech (tachyphemia or cluttered speech) are typical and are similar to that which occur in Parkinson disease, but in contrast to Parkinson disease, there is no slowness (bradykinesia) or muscle stiffness (rigidity). Finally, some patients with PSP present with cognitive impairment, resembling Alzheimer disease or frontotemporal dementia. Most patients with atypical presentations ultimately develop abnormalities of eye movement, speech, swallowing and gait (Richardson syndrome) in a few years. Thus, the diagnosis of PSP typically becomes more certain as the disease progresses.

Impaired eye movements eventually make reading, driving, and interpersonal eye contact difficult or impossible. Abnormal eyelid control causes the eyes to close involuntarily (blepharospasm) for seconds or more, and some affected individuals may not be able to open their eyes (eye opening apraxia), even when a spasm stops. Other patients have trouble closing their eyes or may blink less than normal, causing the eyes to become dry and red.

Muscles of the body may contract involuntarily, causing the affect body part (e.g., the upper or lower limbs) to assume bizarre postures. This is called dystonia. Blepharospasm is a form of dystonia affecting the muscles around the eyes.

A mild or moderate degree of mental impairment eventually occurs in most patients, and this may be misdiagnosed as Alzheimer disease (AD) when it occurs early in the illness, before significant difficulties with speech, balance and eye movements appear. (For more information on Alzheimer disease, please choose "Alzheimer" as your search term in the Rare Disease Database.)

Some patients experience sleep disturbances such as frequent awakenings and changes in sleeping patterns. Sleep disturbances may be a sign of depression or may be a side effect of a medication. REM (rapid eye movement) sleep behavior disorder is not a characteristic of PSP but is a characteristic of dementia with Lewy bodies, Parkinson disease and multiple system atrophy. In REM sleep behavior disorder, patients talk and move during dream sleep, and the movement can result in personal injury or injury to a bed partner.


The cause of progressive supranuclear palsy is not known, but it is a form of tauopathy, in which abnormal phosphorylation of the protein tau leads to destruction of vital protein filaments in nerve cells, causing their death. Recent work suggests that the disease is at least partly genetic. Many researchers now believe that various genetic and environmental factors contribute to the development of this disorder.

In the medical literature, the word "tauopathies" is used to refer to several neurodegenerative disorders including PSP, in which tau is mishandled. Other neurodegenerative disorders classified as tauopathies include corticobasal degeneration and Pick's disease.

Patients with a family history of PSP are very rare, and the underlying genetic abnormality is unknown in these families. Some cases of PSP are linked to a mutation or genetic variation in the gene MAPT, which helps to produce (codes for) the tau protein. This gene resides on chromosome 17 (17q21.1). Variants of least three other genes (STX6, EIF2AK3, and MOBP) are associated with an increased the risk of developing PSP. The study of genetic mechanisms should eventually lead to effective medical therapies.

Affected Populations

PSP is under-diagnosed, so it is difficult to know how many people are affected. This disorder is believed to affect approximately 20,000 people in the United States. However, far fewer cases have been diagnosed. According to some reports, PSP is estimated to affect as many as 5 in 100,000 people. The onset of this disorder occurs between 45 and 75 years of age, with the average age of onset at about 63 years. Males are affected more often than females.

Standard Therapies


The diagnosis of progressive supranuclear palsy may be suspected based upon a thorough clinical evaluation, a detailed patient history, and identification of characteristic physical findings.


Treatment of progressive supranuclear palsy is symptomatic and supportive. There is no cure at the present time. In some cases, drugs used to treat Parkinson disease (antiparkinsonian agents), such as levodopa, may be of some benefit in relieving symptoms the slowness, but the effect is usually limited and temporary. Antidepressant medications are of some benefit in some cases. The use of these drugs should be monitored carefully by a neurologist experienced in their administration.

Walking aids such as a walker weighted in front and wearing shoes with built-up heels may help in preventing affected individuals from falling backwards. Bifocals or special glasses with prisms may be prescribed for some individuals with PSP to treat certain difficulties in eyesight (i.e., difficulty looking down).

When a patient can no longer swallow, a surgical procedure known as percutaneous gastrostomy can be performed, depending upon the patient's wishes and quality of life. In this procedure, a tube is placed through the skin of the abdomen into the stomach (intestine) to allow for sufficient feeding.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll free: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:

For information about clinical trials conducted in Europe, contact:



Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394-400.

Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-279.

Williams DR, Lees AJ, Wherrett JR, Steele JC. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology 2008;70:566-573.

Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240-50.

Pelak VS, Hall DA. Neuro-ophthalmic manifestations of neurodegenerative disease. Ophthalmol Clin North Am. 2004;17:311-20.


Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Microtubule-Associated Protein Tau; MAPT. Entry No: 157140. Last Updated 09/10/2013. Available at: . Accessed Jan 2, 2014.

Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Supranuclear Palsy, Progressive; 1; PSNP1. Entry No: 601104. Last Updated 05/31/2012. Available at: . Accessed Jan 2, 2014.


CurePSP: Foundation for PSP l CBD & Related Brain Diseases

30 E. Padonia Road, Suite 201

Timonium, MD 21093

Tel: (410)785-7004

Fax: (410)785-7009

Tel: (800)457-4777



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981


Progressive Supranuclear Palsy Association UK

PSP House

167 Watling Street West


Northamptonshire, NN12 6BX

United Kingdom

Tel: 01327322410

Fax: 01327322412



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


National Parkinson Foundation, Inc.

1501 NW 9th Ave/Bob Hope Road

Miami, FL 33136-1494

Tel: (305)243-6666

Fax: (305)243-6073

Tel: (800)327-4545



UCSF Memory and Aging Center

350 Parnassus Avenue

Suite 905

San Francisco, CA 94117

Tel: (415)476-6880

Fax: (415)476-4800



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see